✦ LIBER ✦

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate

✍ Scribed by Yasuharu Nakashima; Masakazu Kondo; Hiroshi Harada; Takahiko Horiuchi; Takashi Ishinishi; Hiroshi Jojima; Koji Kuroda; Hisaaki Miyahara; Ryuji Nagamine; Hitoshi Nakashima; Takeshi Otsuka; Isao Saikawa; Eisuke Shono; Eiichi Suematsu; Tomomi Tsuru; Ken Wada; Yukihide Iwamoto

Publisher: Springer
Year: 2010
Tongue: English
Weight: 348 KB
Volume: 20
Category: Article
ISSN: 1439-7595
DOI: 10.1007/s10165-010-0290-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-blind randomized controlled clini

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

✍ R. N. Maini; P. C. Taylor; J. Szechinski; K. Pavelka; J. Bröll; G. Balint; P. Em 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 3 views

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 3 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa

Study of active controlled tocilizumab m

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

✍ Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutom 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 250 KB

Humanized anti-interleukin-6-receptor an

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

✍ Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuh 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 191 KB